Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | RHOA | P61586 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.35 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670550 | 0.89 | RHOA (0.39) | BRAFRHOACNR1CNR2 | |
| SCHEMBL19706268 | 0.88 | RHOA (0.46) | BRAFRHOACREBBPBRD4FYN | |
| SCHEMBL19670539 | 0.88 | BRAF (0.37) | BRAFRHOACNR1KDM1ACNR2 | |
| SCHEMBL19365783 | 0.86 | RHOA (0.45) | BRAFRHOACREBBPBRD4FYN | |
| SCHEMBL19706127 | 0.85 | TSHR (0.47) | TP53POLBMAPTCNR2 | |
| SCHEMBL19706246 | 0.82 | BRAF (0.37) | BRAFFYNMAPTKDM1ACNR2 | |
| SCHEMBL19706271 | 0.82 | CNR2 (0.36) | BRAFCNR1FYNTP53POLB | |
| SCHEMBL17618831 | 0.81 | BRAF (0.43) | BRAFRHOACNR1CREBBPBRD4 | |
| SCHEMBL19706131 | 0.79 | POLB (0.42) | BRAFFYNPOLBMAPTKDM1A | |
| SCHEMBL16776225 | 0.79 | CREBBP (0.43) | BRAFRHOACNR1CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | BRAF 3419/4885RHOA 4798/4885CNR1 2946/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | BRAF 3419/4885RHOA 4798/4885CNR1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.